Roman Yelensky is a visionary leader in the biotechnology sector, currently serving as the Founder and CEO of Serum Detect, Inc., a pioneering startup at the forefront of liquid biopsy technology for early cancer detection. Under his guidance, Serum Detect is harnessing the power of...
Roman Yelensky is a visionary leader in the biotechnology sector, currently serving as the Founder and CEO of Serum Detect, Inc., a pioneering startup at the forefront of liquid biopsy technology for early cancer detection. Under his guidance, Serum Detect is harnessing the power of tumor immune surveillance to revolutionize how we identify cancer at its nascent stages, significantly improving the chances of successful treatment and patient outcomes. With a strong foundation in pharmacogenetics, biomarker discovery, and DNA sequencing, Roman is adept at navigating the complexities of the life sciences landscape, ensuring that Serum Detect remains at the cutting edge of innovation.
Before establishing Serum Detect, Roman made significant contributions as the first employee and Chief Technology Officer at Gritstone bio, where he played a crucial role in developing the EDGE tumor antigen identification platform. His leadership in the implementation of Good Manufacturing Practices (GMP) not only advanced the platform's capabilities but also set a high standard for operational excellence in the biotech industry. Roman's expertise in clinical trials and data analysis further enhances his ability to drive impactful research and development initiatives.
At Serum Detect, Roman is focused on key projects that aim to refine liquid biopsy methodologies, leveraging advanced biochemistry techniques to enhance the sensitivity and specificity of cancer detection. His commitment to innovation is matched by his passion for collaboration, as he works closely with a talented team of scientists and industry experts to push the boundaries of what is possible in oncology. With a deep understanding of population genetics and a strategic vision for the future of cancer diagnostics, Roman Yelensky is poised to make a lasting impact on the field of early cancer detection.
